Effects of COX Inhibition on Blood Pressure and Kidney Function in ACE Inhibitor-Treated Blacks and Hispanics
Abstract
Cyclo-oxygenase (COX) inhibitors attenuate the antihypertensive effects of angiotensin-converting enzyme (ACE) inhibitors and reduce kidney function. The study tests the hypothesis that these two classes of drugs have similar effects on glomerular filtration rate (GFR) and 24-hour blood pressure. The primary endpoint was change in 24-hour systolic blood pressure. Using a randomized crossover design, 25 black and Hispanic hypertensive participants (mean age 58±3 years) with osteoarthritis were studied. All participants received an ACE inhibitor at baseline. Once systolic blood pressure was <140 mm Hg, either celecoxib 200 mg/d or diclofenac 75 mg twice daily for 4 weeks was started. After measurements were obtained, all participants underwent a 2-week washout period and crossed over to the other drug for 4 weeks. A significant difference in mean 24-hour systolic blood pressure was noted between groups at 4 weeks (+4.1±1.1 mm Hg diclofenac versus +0.6±0.6 mm Hg celecoxib; P =0.01). However, because celecoxib has duration of action shorter than 24 hours, we compared ambulatory values at celecoxib trough and peak activities. At peak, no difference in systolic blood pressure was noted between agents (+3.6±0.04 mm Hg diclofenac versus +4.2±1.9 mm Hg celecoxib; P =0.67). GFR was also differentially affected at 24 hours (−9.9±2.4 mL/min diclofenac versus −0.4±1.2 mL/min celecoxib; P =0.01). We conclude that diclofenac and celecoxib increase systolic blood pressure at peak levels; however, these agents differ in their 24-hour effects. Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The systolic blood pressure increase with NSAIDs in ACE inhibitor users ranged from 5 to 10 mm Hg.
“The SBP increase with NSAIDs in ACE inhibitor users ranged from 5 to 10 mm Hg.196–199”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [199]
Cites
Silverstein, F. E., Faich, G. A., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G. M., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,144 · see citing works
Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis
Johnson, A. G., Nguyen, T. V., & Day, R. O. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00011 · Cited by 717 · see citing works
Catella-Lawson, F., McAdam, B. F., Morrison, B. W., Kapoor, S. C., Kujubu, D. A., Antes, L. M., Lasseter, K. C., Quan, H., Gertz, B. J., & FitzGerald, G. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 596 · see citing works
A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure
Pope, J. E. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410040045007 · Cited by 527 · see citing works
Douglas, J. G. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.525 · Cited by 431 · see citing works
Whelton, A., White, W. B., Bello, A. E., Puma, J. A., & Fort, J. G. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02661-9 · Cited by 310 · see citing works
Wolfe, F., & Sharp, J. T. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9 · Cited by 274 · see citing works
Circadian variation in cardiovascular events
Muller, J. E. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00278-7 · Cited by 210 · see citing works
Renal Safety and Tolerability of Celecoxib, a Novel Cyclooxygenase-2 Inhibitor
Whelton, A., Maurath, C. J., Verburg, K. M., & Geis, G. (2000) · American Journal of Therapeutics · doi:10.1097/00045391-200007030-00004 · Cited by 167 · see citing works
Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease
Spence, J. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02327-x · Cited by 165 · see citing works
Schwartz, J. I., Vandormael, K., Malice, M., Kalyani, R. N., Lasseter, K. C., Holmes, G. B., Gertz, B. J., Gottesdiener, K. M., Laurenzi, M. W., Redfern, K. ‐., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126182 · Cited by 161 · see citing works
Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors
White, W. B., Kent, J. D., Taylor, A. A., Verburg, K. M., Lefkowith, J. B., & Whelton, A. (2002) · Hypertension · doi:10.1161/01.hyp.0000014323.99765.16 · Cited by 149 · see citing works
Cyclooxygenase-2 inhibition and renal physiology
Harris, R. C. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02232-4 · Cited by 132 · see citing works
Morgan, T. O., Anderson, A., & Bertram, D. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01204-8 · Cited by 102 · see citing works
Single‐dose and steady‐state pharmacokinetics of celecoxib in children
Stempak, D., Gammon, J., Klein, J., Koren, G., & Baruchel, S. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129322 · Cited by 87 · see citing works
Does cyclooxygenase-2 affect blood pressure?
Cheng, H., & Harris, R. C. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0016-y · Cited by 19 · see citing works
NSAIDs and Hypertension--Reply
Curhan, G. C., & Stampfer, M. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1115-a · Cited by 17 · see citing works
EFFECTS OF NAPROXEN ON RENAL FUNCTION IN OLDER PATIENTS WITH MILD TO MODERATE RENAL DYSFUNCTION
Simon, L. S., Basch, C. M., Young, D. Y., & ROBINSON, D. R. (1992) · Lara D. Veeken · doi:10.1093/rheumatology/31.3.163 · Cited by 11 · see citing works
Flagged first, then by citations
1 of the 19 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works
Self-citationPharmacological Management of Persistent Pain in Older Persons
American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02376.x · Cited by 1,028 · see citing works
Pharmacological Management of Persistent Pain in Older Persons
American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons, R. W. P. F. T. A. G. S. O. A. A. I. J. A. G. S. 2. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00699.x · Cited by 916 · see citing works
Secondary arterial hypertension: when, who, and how to screen?
Rimoldi, S. F., Scherrer, U., & Messerli, F. H. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht534 · Cited by 393 · see citing works
“NSAIDs may increase mean 24 h systolic BP by 4–5 mmHg, particularly in patients with pre-existing hypertension and in salt-sensitive patients.(21) Therefore, in patients with hypertension, acetaminophen is recommended as analgesic of choice.”
BackgroundBradykinin receptor ligands: therapeutic perspectives
Marceau, F., & Regoli, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1522 · Cited by 375 · see citing works
“More simply, kinin receptor antagonists could exert drug interactions similar to the cyclooxygenase-1 or -2 inhibitors, which have been shown to reduce the therapeutic effects of ACE inhibitors in human”
Dobrev, D., Heijman, J., Hiram, R., Li, N., & Nattel, S. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00759-w · Cited by 274 · see citing works
Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P. V., Levin, B., Eagle, C. J., Hawk, E. T., Lechuga, M., Zauber, A. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.636746 · Cited by 273 · see citing works
Adverse drug interactions involving common prescription and over-the-counter analgesic agents
Hersh, E. V., Pinto, A., & Moore, P. A. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.12.003 · Cited by 183 · see citing works
Signaling by the Angiotensin-Converting Enzyme
Fleming, I. (2006) · Circulation Research · doi:10.1161/01.res.0000217340.40936.53 · Cited by 171 · see citing works
Ruschitzka, F., Borer, J. S., Krum, H., Flammer, A. J., Yeomans, N. D., Libby, P., Lüscher, T. F., Solomon, D. H., Husni, M. E., Graham, D. Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx508 · Cited by 130 · see citing works
Cardiovascular Effects of the Cyclooxygenase Inhibitors
White, W. B. (2007) · Hypertension · doi:10.1161/01.hyp.0000258106.74139.25 · Cited by 128 · see citing works
COX-2 Selective Inhibitors in the Treatment of Osteoarthritis
Laine, L., White, W. B., Rostom, A., & Hochberg, M. C. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2007.10.004 · Cited by 123 · see citing works
Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting
Guan, Y., Zhang, Y., Wu, J., Qi, Z., Yang, G., Dou, D., Gao, Y., Chen, L., Zhang, X., Davis, L. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29838 · Cited by 109 · see citing works
Aljadhey, H. S., Tu, W., Hansen, R. A., Blalock, S. J., Brater, D. C., & Murray, M. D. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-93 · Cited by 89 · see citing works
“[9-24] but not observational studies, which are more representative to real-world clinical settings.”
The Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressure in Hypertensive Patients
Snowden, S., & Nelson, R. J. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e31821ddcf4 · Cited by 81 · see citing works
“NSAIDs are a widely used class of medications, especially in the elderly and patients with OA and RA.44 With 1/3 of Americans having hypertension, there is a high likelihood of coadministration of antihypertensives and NSAIDs.”
BackgroundInfluentialKohlstedt, K., Busse, R., & Fleming, I. (2004) · Hypertension · doi:10.1161/01.hyp.0000150159.48992.11 · Cited by 79 · see citing works
Comparing Rates of Dyspepsia with Coxibs vs NSAID+PPI: A Meta-Analysis
Spiegel, B. M. R., Farid, M., Dulai, G. S., Gralnek, I. M., & Kanwal, F. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.020 · Cited by 74 · see citing works
Khan, S. I., Andrews, K. L., & Chin-Dusting, J. P. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174262 · Cited by 69 · see citing works
“examined BP increases at peak concentrations with celecoxib and diclofenac use, given the shorter half-life of the former [30].”
BackgroundNew fACEs to the Renin-Angiotensin System
Fleming, I., Kohlstedt, K., & Busse, R. (2005) · Physiology · doi:10.1152/physiol.00003.2005 · Cited by 70 · see citing works
Morrison, A., Ramey, D. R., van Adelsberg, J., & Watson, D. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x219553 · Cited by 61 · see citing works
Emerging Roles and Therapeutic Applications of Arachidonic Acid Pathways in Cardiometabolic Diseases
Hu, Y., Li, W., Cheng, X., Yang, H., She, Z., Cai, J., Li, H., & Zhang, X.-J. (2024) · Circulation Research · doi:10.1161/circresaha.124.324383 · Cited by 60 · see citing works
“337,347 Furthermore, the functional range of COX-1 inhibition by aspirin was compromised by ibuprofen in patients with osteoarthritis and stable ischemic heart disease.”
BackgroundHinz, B., Dormann, H., & Brune, K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21540 · Cited by 56 · see citing works
Amanullah, A., Upadhyay, A., Dhiman, R., Singh, S., Kumar, A., Ahirwar, D. K., Gutti, R. K., & Mishra, A. (2022) · Cancers · doi:10.3390/cancers14184385 · Cited by 53 · see citing works
“Diclofenac, in combination with angiotensin-converting enzyme (ACE) inhibitors, have been found to cause increased systolic blood pressure, thereby reducing the effects of ACE inhibitors [73].”
BackgroundBlue, N. R., Murray-Krezan, C. M., Drake-Lavelle, S., Weinberg, D., Holbrook, B. D., Katukuri, V. R., Leeman, L. M., & Mozurkewich, E. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.02.016 · Cited by 53 · see citing works
Secondary Hypertension: Interfering Substances
Grossman, E., & Messerli, F. H. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07758.x · Cited by 49 · see citing works
Walker, C. (2018) · International Journal of Rheumatology · doi:10.1155/2018/1302835 · Cited by 49 · see citing works
“The ambulatory BP effects of diclofenac have been investigated in relatively small populations (< 30 patients) [66, 67], and the data should therefore be treated cautiously.”
BackgroundWhite, W. B., Schnitzer, T. J., Fleming, R., Duquesroix, B., & Beekman, M. J. H. I. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.014 · Cited by 47 · see citing works
Defining the Problem of Treating the Patient with Hypertension and Arthritis Pain
White, W. B. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.002 · Cited by 46 · see citing works
Yılmaz, B., Aşçı, A., & Palabıyık, Ş. S. (2011) · Journal of Chromatographic Science · doi:10.1093/chrsci/49.6.422 · Cited by 46 · see citing works
GC–MS Determination of Diclofenac in Human Plasma
Yılmaz, B. (2010) · Chromatographia · doi:10.1365/s10337-010-1479-z · Cited by 45 · see citing works
Kaphalia, L., Kaphalia, B. S., Kumar, S., Kanz, M. F., & Treinen–Moslen, M. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.10.045 · Cited by 41 · see citing works
Cardiovascular risk, hypertension, and NSAIDs
White, W. B. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0020-3 · Cited by 39 · see citing works
“In a smaller trial, Izhar et al. [ 42 ] studied the effects of celecoxib and diclofenac on ambulatory BP and glomerular filtration rates in a double-blind crossover study.”
BackgroundTurtle, E. J., Dear, J. W., & Webb, D. J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12032 · Cited by 48 · see citing works
Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity
Singh, B. K., Haque, S. E., & Pillai, K. K. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.856881 · Cited by 34 · see citing works
“6 mmHg) and GFR was significantly reduced by diclofenac but not by celecoxib [47].”
BackgroundZullo, A. R., Danko, K. J., Moyo, P., Adam, G. P., Riester, M. R., Kimmel, H. J., Panagiotou, O. A., Beaudoin, F. L., Carr, D. B., & Balk, E. M. (2020) · doi:10.23970/ahrqepctb37 · Cited by 34 · see citing works
Verhoeven, F., Totoson, P., Marie, C., Prigent‐Tessier, A., Wendling, D., Tournier-Nappey, M., Prati, C., & Demougeot, C. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.033 · Cited by 31 · see citing works
Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys.
Rahman, S., & Malcoun, A. (2014) · Primary Care · doi:10.1016/j.pop.2014.09.001 · Cited by 34 · see citing works
Cyclooxygenase-2 inhibitors and cardiovascular risk
Solomon, S. D. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000245740.85829.4f · Cited by 27 · see citing works
Hegazy, R. M., Alashhab, M., & Amin, M. (2011) · Journal of Toxicology · doi:10.1155/2011/862153 · Cited by 23 · see citing works
“In two recent, randomized double-blind trials for 6 weeks of OA patients taking antihypertensive agents, the study participants taking celecoxib 200 mg daily were less likely to experience renal adverse events than the group receiving rofecoxib 25 mg daily [33].”
BackgroundIbrahim, M. A., Abdelzaher, W. Y., Rofaeil, R. R., & Abdelwahab, S. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.102 · Cited by 18 · see citing works
Effects of Naproxcinod on Blood Pressure in Patients With Osteoarthritis
White, W. B., Schnitzer, T. J., Bakris, G. L., Frayssinet, H., Duquesroix, B., & Weber, M. A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.12.046 · Cited by 18 · see citing works
Self-citationVilla, J., Cano, A., Franco, D., Monsalve, M., Hincapié-García, J. A., & Amariles, P. (2014) · Atención Primaria · doi:10.1016/j.aprim.2013.11.010 · Cited by 17 · see citing works
Cardiovascular risk, hypertension, and NSAIDs
White, W. B. (2007) · Current Pain and Headache Reports · doi:10.1007/s11916-007-0229-x · Cited by 17 · see citing works
“In a smaller trial, Izhar et al. [ 42 ] studied the effects of celecoxib and diclofenac on ambulatory BP and glomerular filtration rates in a double-blind crossover study.”
BackgroundZhang, D., Chen, L., Zhang, Y.-H., Yang, G., Dou, D., Gao, Y., Zhang, X., Kong, X., Zhao, P., Pu, D., et al. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.99 · Cited by 16 · see citing works
Square Wave Voltammetric Determination of Diclofenac in Pharmaceutical Preparations and Human Serum.
Ciltas, U., Yılmaz, B., Kaban, S., Akcay, B. K., & Nazik, G. (2015) · Europe PMC (PubMed Central) · Cited by 15 · see citing works
Blood Pressure Destabilization on Nonsteroidal Antiinflammatory Agents
White, W. B., & Campbell, P. H. (2010) · Circulation · doi:10.1161/circulationaha.110.984054 · Cited by 13 · see citing works
Bawolak, M., Touzin, K., Moreau, M. E., Désormeaux, A., Adam, A. A., & Marceau, F. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.09.004 · Cited by 13 · see citing works
Augmented cyclooxygenase-2 effects on renal function during varying states of angiotensin II
Green, T., Rodriguez, J., & Navar, L. G. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00609.2009 · Cited by 13 · see citing works
“Furthermore, the potential of COX-2 to mediate the prostaglandin antagonism of hypertension is evident from the effects of COX-2 inhibitors to increase blood pressure in ACE inhibitor-treated patients (18).”
BackgroundIdentifying and Managing Factors that Interfere with or Worsen Blood Pressure Control
Basile, J., & Bloch, M. J. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2120 · Cited by 10 · see citing works
“However, the effect of celecoxib on BP appears to increase with higher doses and more frequent administration.(69) Recently, a novel class of NSAIDs has been developed, the COX-inhibiting nitric oxide donors, of which naproxcinod is the fi rst to become commercially available.”
BackgroundSahoo, N. K., Sahu, M., Rao, P. S., & Ghosh, G. (2015) · Journal of Analytical Chemistry · doi:10.1134/s1061934815040115 · Cited by 9 · see citing works
Chou, R., Helfand, M., & Peterson, K. (2006) · Cited by 9 · see citing works
Clinical Pharmacology of Antihypertensive Therapy
Taylor, A. A., & Pool, J. L. (2005) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.02.006 · Cited by 8 · see citing works
Pharmakotherapie bei Arthroseschmerzen
Nees, T. A., & Schiltenwolf, M. (2018) · Der Schmerz · doi:10.1007/s00482-018-0286-6 · Cited by 8 · see citing works
Lattuca, B., Khoueiry, Z., Malclès, G., Davy, J., & Leclercq, F. (2013) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523011312010006 · Cited by 6 · see citing works
“COX-inhibitors and ACE-inhibitors have been compared, as regards GFR and 24-hour blood pressure in 25 Black and Hispanic hypertensive participants (mean age 58+/-3 years) with osteoarthritis [76].”
BackgroundGowayed, M. A., Abdel-Bary, A., & El-Tahan, R. A. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00488-9 · Cited by 6 · see citing works
Angiotensin-Converting Enzyme Inhibitors
Sica, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2766-1.00020-x · Cited by 6 · see citing works
Angiotensin-Converting Enzyme Inhibitors
Sica, D. A., & Gehr, T. W. B. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0258-5.50155-1 · Cited by 5 · see citing works
Goswami, S., Jain, S., Chudasama, H., & Santani, D. D. (2011) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2011.020 · Cited by 2 · see citing works
“In a crossover clinical trial involving hypertensive and osteoarthritic patients stabilized on ACEI therapy, a signifi cant increase in 24 h SBP and DBP was found, where celecoxib signifi cantly elevated BP at its peak level (18) .”
BackgroundTreating Pain and Inflammation in Hypertension
White, W. B., Marfatia, R., & Baker, W. L. (2012) · Springer eBooks · doi:10.1007/978-88-470-2601-8_28 · Cited by 2 · see citing works
Impact of NSAIDs on cardiovascular risk and hypertension
White, W. B., & Cruz, C. (2011) · Italian Journal of Medicine · doi:10.1016/j.itjm.2011.04.007 · Cited by 2 · see citing works
Pharmakotherapie bei Arthroseschmerzen
Nees, T. A., & Schiltenwolf, M. (2018) · rheuma plus · doi:10.1007/s12688-018-0215-x · Cited by 1 · see citing works
Study of Enalapril and Diclofenac Sodium in Osteoarthritic Hypertensive Patients
Goswami, M. P. D. S. (2020) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v8i5.05 · Cited by 1 · see citing works
“As shown in previous clinical studies, NSAIDs like rofecoxib, aspirin, indomethacin, ibuprofen, diclofenac, celecoxib or piroxicam have remarkably blunted the BP control efficacy of ACEIs (11-15) in hypertensive and/or osteoarthritic patients.”
ResultAn Assessement of the Severity of Knee Osteoarthritis in the University of Benin Teaching Hospital
Idiake, J. O., Lawrence, L., Udezi, W., Usifoh, S. F., & Agun, M. I. (2021) · South Asian Research Journal of Pharmaceutical Sciences · doi:10.36346/sarjps.2021.v03i02.001 · Cited by 1 · see citing works
Impact of NSAIDs on cardiovascular risk and hypertension
White, W. B., & Cruz, C. (2013) · Italian Journal of Medicine · doi:10.4081/itjm.2011.175 · Cited by 1 · see citing works
Comparing Rates of Dyspepsia with Coxibs vs NSAIDPPI
Spiegel, B. M. R., Farid, M., Dulai, G. S., & Gralnek, I. M. (2006) · Cited by 1 · see citing works
Manolis, A. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734299250.793571584 · Cited by 1 · see citing works
Managing Headache in Older People
Sacco, S., & Carolei, A. (2011) · Springer eBooks · doi:10.1007/978-88-470-1700-9_47
Rare and Unusual Forms of Hypertension
Grossman, E., & Messerli, F. H. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3053-9.50018-4
Rare and Unusual Forms of Hypertension
Grossman, E., & Messerli, F. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2766-1.00012-0
Angiotensin-Converting Enzyme Inhibitors
Sica, D. A. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3053-9.50026-3
Ajibade, T. O., Akinrinde, A. S., Adetona, M. O., Oyagbemi, A. A., Adedapo, A. D. A., Larbie, C., Omóbòwálé, T. O., Ola‐Davies, O. E., Saba, A. B., Adedapo, A. A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1175324/v1
Radi, Z. A. (2012) · doi:10.1002/9781118351918.ch3
Smolensky, M. H., Hermida, R. C., Sackett-Lundeen, L. L., Hermida‐Ayala, R. G., & Geng, Y. (2022) · Comprehensive physiology · doi:10.1002/cphy.c220014
An Analytical Study of NSAIDs Affecting Heart Functions
(2022) · International Journal of Bio-Medical Informatics and e-Health · doi:10.30534/ijbmieh/2022/021062022
Smolensky, M. H., Hermida, R. C., Sackett-Lundeen, L. L., Hermida‐Ayala, R. G., & Geng, Y. (2022) · Comprehensive physiology · doi:10.1002/j.2040-4603.2022.tb00245.x
- Authors
- Izhar, M., Alausa, T., Folker, A., Hung, E., & Bakris, G. L.
- Affiliations
- Rush University Medical Center (US)
- ORCID
- Bakris, George L.
- Venue
- Hypertension
- Published
- 2004-03
- Volume
- 43
- Issue
- 3
- Pages
- 573-577
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2162138099
- Cited by
- 77
- References
- 19
- Citations by year
- 2024: 1 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 6 · 2017: 3 · 2015: 2 · 2014: 2 · 2013: 4 · 2012: 6
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- cyclooxygenase inhibitors, ACE inhibitors, celecoxib, diclofenac, blood pressure, glomerular filtration rate, renal function, drug interactions, osteoarthritis, racial differences, Hispanic patients, Black patients, ambulatory blood pressure, dosing frequency
- MeSH terms
- Celecoxib, Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Anti-Inflammatory Agents, Non-Steroidal, Antihypertensive Agents, Blood Pressure, Diclofenac, Female, Glomerular Filtration Rate, Hispanic or Latino, Humans, Hypertension, Isoenzymes, Kidney, Male, Membrane Proteins, Middle Aged, Osteoarthritis, Prostaglandin-Endoperoxide Synthases, Pyrazoles, Sulfonamides, Cyclooxygenase Inhibitors, Cross-Over Studies, Blood Pressure Monitoring, Ambulatory, Gastrointestinal Tract, Black People, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
